PLoS ONE (Jan 2022)

Real-world data on vitamin D supplementation and its impacts in systemic lupus erythematosus: Cross-sectional analysis of a lupus registry of nationwide institutions (LUNA).

  • Keigo Hayashi,
  • Ken-Ei Sada,
  • Yosuke Asano,
  • Yu Katayama,
  • Keiji Ohashi,
  • Michiko Morishita,
  • Yoshia Miyawaki,
  • Haruki Watanabe,
  • Takayuki Katsuyama,
  • Mariko Narazaki,
  • Yoshinori Matsumoto,
  • Nobuyuki Yajima,
  • Ryusuke Yoshimi,
  • Yasuhiro Shimojima,
  • Shigeru Ohno,
  • Hiroshi Kajiyama,
  • Kunihiro Ichinose,
  • Shuzo Sato,
  • Michio Fujiwara,
  • Jun Wada

DOI
https://doi.org/10.1371/journal.pone.0270569
Journal volume & issue
Vol. 17, no. 6
p. e0270569

Abstract

Read online

BackgroundAlthough vitamin D concentration is reportedly associated with the pathogenesis and pathology of systemic lupus erythematosus (SLE), benefits of vitamin D supplementation in SLE patients have not been elucidated, to our knowledge. We investigated the clinical impacts of vitamin D supplementation in SLE.MethodsA cross-sectional analysis was performed using data from a lupus registry of nationwide institutions. We evaluated vitamin D supplementation status associated with disease-related Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) as a parameter of long-term disease activity control.ResultsOf the enrolled 870 patients (mean age: 45 years, mean disease duration: 153 months), 426 (49%) received vitamin D supplementation. Patients with vitamin D supplementation were younger (43.2 vs 47.5 years, P ConclusionsEven with a possible Vitamin D deficiency and a high risk of bone fractures in SLE patients, only half of our cohort received its supplementation. The effect of vitamin D supplementation for disease activity control was not observed.